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Background: Most	 patients	 with	 methotrexate-	associated	 lymphoproliferative	




















remission.	 No	 association	 was	 observed	 between	 PD-	L1	 expression	 levels	 and	
clinical	 findings	 at	 diagnosis,	 suggesting	 that	 PD-	L1	 expression	 in	 tumor	 cells	
influences	the	pathogenesis	of	CHL-	type	MTX-	LPD	after	MTX	discontinuation.
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1 	 | 	 INTRODUCTION





and	 infectious	 diseases	 related	 to	 immunosuppression.	
Furthermore,	 in	 recent	 years,	 the	 number	 of	 cases	 re-
porting	 MTX-	associated	 lymphoproliferative	 disorders	
(MTX-	LPD)	has	increased	rapidly	in	Japan.1–	6	MTX-	LPD	
is	also	classified	as	“other	 iatrogenic	 immunodeficiency-	
associated	 lymphoproliferative	 disorder”	 in	 the	 4th	 edi-













MTX-	LPD	 has	 similar	 histopathology	 to	 that	 of	 de	 novo	
lymphoma,	many	patients	exhibit	spontaneous	remission	
after	 MTX	 discontinuation.4,12,13	 We	 previously	 reported	







death-	ligand	 1	 (PD-	L1)	 pathway	 in	 various	 tumors	 have	
recently	attracted	attention.	PD-	L1	 is	highly	expressed	 in	





with	 9p24.1	 amplification.18	 In	 addition,	 a	 recent	 study	
noted	that	anti-	PD-	1	antibody	could	be	an	effective	treat-
ment	option	for	de	novo	CHL.19	Therefore,	we	investigated	
the	 relationship	 between	 PD-	L1	 expression	 and	 clinical	
features	 of	 DLBCL-	type	 and	 CHL-	type	 MTX-	LPD.	 This	
study	 focused	 on	 examining	 the	 role	 of	 PD-	1/PD-	L1	 in	
CHL-	type	MTX-	LPD	prognosis	after	MTX	discontinuation.




whereas	 the	 remaining	 33  had	 CHL-	type	 MTX-	LPD	
(Figure  2).	 The	 Eastern	 Cooperative	 Oncology	 Group	




Review	 Board	 of	 Okayama	 University	 (reference	 num-
bers:	 1607-	016	 and	 2007-	033).	 Comprehensive	 informed	
consent	was	obtained	from	all	patients	through	an	opt-	out	
methodology	at	Okayama	University.
2.2	 |	 Histological examination




fin	 sections	 using	 antibodies	 against	 CD3	 (1:200,	 LN10;	
Novocastra),	CD5	(1:100,	4C7;	Novocastra),	CD10	(1:100,	
56C6;	 Novocastra),	 CD15	 (1:50,	 Carb-	3;	 DAKO),	 CD20	
(1:100,	L26;	DAKO),	CD30	(1:40,	Ber-	H2;	DAKO),	CD79a	
(1:100,	 JCB117;	 DAKO),	 Ki-	67	 (1:2500,	 MIB-	1;	 DAKO),	
and	PD-	L1	(1:400,	E1LN3;	Cell	Signaling	Technology)	and	
samples	 were	 analyzed	 using	 a	 Bond	 III	 Stainer	 (Leica	
Biosystems).
2.3	 |	 Evaluation of PD- L1 expression
The	expression	of	PD-	L1	was	examined	in	20	DLBCL-	type	
and	24	CHL-	type	MTX-	LPD	cases	and	the	percentage	of	








K E Y W O R D S
classic	Hodgkin	lymphoma,	diffuse	large	B-	cell	lymphoma,	methotrexate-	associated	
lymphoproliferative	disorder,	programmed	cell	death-	ligand	1,	rheumatoid	arthritis




as	 “PD-	L1  low	 expression	 group”	 for	 cases	 with	 PD-	L1-	
positive	rate	≤50%	(score	1	or	2).
Cells	 in	 the	 microenvironment,	 such	 as	 histiocytes,	
also	 express	 PD-	L1;	 therefore,	 the	 specimens	 were	 also	
analyzed	 for	 PD-	L1	 expression	 in	 the	 microenviron-
ment.	 Cases	 were	 defined	 as	 “microenvironment	 PD-	L1	
positive”	 when	 accompanied	 by	 non-	neoplastic	 PD-	L1-	
positive	 cells.	 Microenvironment	 PD-	L1	 expression	 was	
differentiated	 from	 tumor	 cell	 expression	 by	 evaluating	
morphology,	 low	 nuclear/cytoplasmic	 ratio,	 and	 non-	
atypical	nuclei	without	atypia.
2.4	 |	 Detection of EBV infection pattern 
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EBV-	encoded	 small	 RNA	 (EBER1;	 Novocastra)	 were	 per-
formed	using	an	automated	Bond	III	Stainer.





2.5	 |	 Statistical analyses
Differences	 between	 laboratory	 data	 and	 patient	 char-
acteristics	 at	 each	 CS	 were	 analyzed	 using	 the	 Mann–	
Whitney	test.	The	correlation	between	the	PD-	L1-	positive	




motherapy	start	was	defined	as	 the	 time	 from	MTX-	LPD	
diagnosis	to	chemotherapy	start	or	death	or	final	follow-	up.	
Follow-	up	 duration	 was	 calculated	 as	 the	 time	 of	 MTX-	
LPD	diagnosis	to	death	from	any	cause	or	final	follow-	up.	
Survival	 curves	 were	 evaluated	 using	 the	 Kaplan–	Meier	
method	and	compared	using	log	rank	tests.	Statistical	anal-
yses	were	performed	using	SPSS	(version	14.0;	SPSS).
3 	 | 	 RESULTS








subtypes.	 There	 was	 a	 higher	 proportion	 of	 female	 pa-
tients	than	male	patients	in	both	subtypes	(Table 1).	The	
Eastern	Cooperative	Oncology	Group	performance	status	




3.2	 |	 Clinicopathological 




was	 69  years	 (55–	82  years)	 with	 a	 predominance	 of	 fe-
males	 (29/39;	 74.4%).	 Twelve	 of	 these	 patients	 (12/31;	
30.8%)	had	an	Eastern	Cooperative	Oncology	Group	per-
formance	 status	 ≥2.	 Twenty-	two	 of	 the	 patients	 (22/39;	







drugs	 such	 as	 prednisolone,	 bucillamine,	 tacrolimus,	
























In	 33	 out	 of	 39	 patients	 with	 DLBCL-	type	 MTX-	LPD,	
MTX	 treatment	 was	 discontinued	 after	 the	 diagnosis	 of	
MTX-	LPD.	Of	these	patients,	27/33	(81.8%)	showed	spon-
taneous	 disappearance	 of	 lesions	 after	 MTX	 discontinu-
ation	and	did	not	need	chemotherapy.	Additionally,	one	
patient	 had	 partial	 remission	 and	 subsequently	 received	
chemotherapy.	 In	 5/33	 (15.1%)	 patients	 the	 lesions	 did	





Moreover,	 6/39	 patients	 with	 DLBCL-	type	 MTX-	LPD	
were	critically	ill	at	the	time	of	diagnosis,	for	which	they	
required	 immediate	 chemotherapy	 in	 addition	 to	 MTX	
discontinuation.	 After	 chemotherapy,	 5/6	 (83.3%)	 of	
these	patients	exhibited	remission,	and	one	died	owing	to	
DLBCL-	type	MTX-	LPD.







Age 67	(32–	84) 69	(55–	82) 64	(32–	84) 0.08
Sex	(male/female) 21/51 10/29 11/22 0.60
PS	≥2 28.8%	(17/59) 38.7%	(12/31) 17.9%	(5/28) 0.09
Clinical	stage	≥3 73.6%	(53/72) 74.4%	(29/39) 72.7%	(24/33) 1.00
Extranodal	disease 45.8%	(33/72) 56.4%	(22/39) 33.3%	(11/33) 0.06
Extranodal	disease	≥2 12 6 6
LDH	above	normal 66.2%	(45/68) 74.3%	(26/35) 57.6%	(19/33) 0.20
sIL−2R	above	normal 86.2%	(56/65) 90.9%	(30/33) 81.3%	(26/32) 0.30
B	symptom	positive 53.4%	(31/58) 53.1%	(17/32) 53.8%	(14/26) 1.00
EBER	positive 88.1%	(59/67) 85.3%	(29/34) 90.9%	(30/33) 0.71
Treatment	for	autoimmune	disease
MTX 100%
Prednisolone 36.1%	(26/72) 23.1%	(9/39) 51.5%	(17/33) 0.02
Other	immunosuppressive	drugs 26.4%	(19/72) 25.6%	(10/39) 27.3%	(9/33) 1.00
Clinical	response	to	MTX	discontinuation 0.09
Complete	remission/partial	remission 74.2%	(49/66) 84.8%	(28/33) 63.9%	(21/33)




No	therapy 52.8%	(38/72) 69.2%	(27/39) 33.3%	(11/33)
Chemotherapy 47.2%	(34/72) 30.8%	(12/39) 66.7%	(22/33)
Clinical	response	to	additional	chemotherapy 0.39
Complete	response 82.3%	(28/34) 91.7%	(11/12) 77.2%	(17/22)
Progressive	disease 17.6%	(6/34) 8.3%	(1/12) 22.7%	(5/22)
Outcome 0.72
Alive 63 35 28
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3.2.3	 |	 Immunohistochemical	phenotype
Atypical	lymphoid	cells	showed	monomorphic	and	dif-
fused	 proliferation	 (Figure  1).	 Immunohistochemical	
staining	 showed	 that	 0%	 (0/39),	 7.4%	 (2/27),	 3.3%	
(3/24),	 and	 89.7%	 (35/39)	 of	 samples	 were	 positive	 for	
CD3,	CD5,	CD10,	and	CD20,	 respectively.	All	 cases	of	
DLBCL-	type	 MTX-	LPD	 showed	 a	 high	 Ki-	67  labeling	
index	 (>30%),	 with	 an	 EBER-	positive	 rate	 of	 85.3%	
(Table 1).
3.3	 |	 Clinicopathological 













diseases,	 and	 21/33	 (63.6%)	 patients	 were	 also	 taking	
other	anti-	RA	drugs	such	as	prednisolone,	bucillamine,	
tacrolimus,	 iguratimod,	 etanercept,	 adalimumab,	 or	
infliximab.
The	 patients	 underwent	 biopsies	 of	 either	 the	 lymph	
nodes,	 bone	 marrow,	 cerebellum,	 skin,	 or	 nasopharynx.	
Extranodal	 lesions	 were	 observed	 in	 11/33	 (33.3%)	 pa-
tients,	including	in	the	lung,	liver,	bone	marrow,	pharynx,	
kidney,	adrenal	gland,	cerebellum,	and	skin,	and	 two	or	




Anemia	 with	 hemoglobin	 levels	 <10.5  g/dl	 was	 ob-
served	 in	 9/30	 (30%)	 patients	 with	 CHL-	type	 MTX-	LPD.	
Low	total	lymphocyte	count	(<600/mm2	or	8%	of	leuko-
cytes)	was	observed	 in	17.6%	 (5/28)	of	 the	patients.	The	
median	LDH	level	at	the	time	of	MTX-	LPD	diagnosis	was	














Relapse	 after	 lesion	 reduction	 was	 observed	 in	 12/33	
patients	(36.4%)	and	11	(91.7%)	of	these	relapsed	patients	
received	 similar	 chemotherapy	 to	 that	 for	 de	 novo	 CHL	
(such	as	ABVD	and	ABVd).	Subsequently,	9/11	(81.8%)	of	
these	 patients	 experienced	 complete	 remission,	 and	 the	




Despite	 MTX	 discontinuation,	 12/33	 (36.4%)	 patients	
with	 CHL-	type	 MTX-	LPD	 showed	 disease	 progression.	
Of	these	patients,	7/12	(58.3%)	experienced	complete	re-









5/33	 (15.1%)	 patients	 died	 during	 or	 after	 chemother-
apy.	The	 cause	 of	 death	 included	 cholecystitis,	 bacterial	
pneumonia,	 and	 disseminated	 intravascular	 coagulation	
syndrome.




MTX	 discontinuation;	 no	 statistically	 significant	 differ-
ences	were	observed.
3.3.3	 |	 Immunohistochemical	phenotype
In	 all	 cases	 of	 patients	 with	 CHL-	type	 MTX-	LPD,	 the	
histopathological	 morphology	 was	 similar	 to	 that	 of	
de	novo	CHL.	HRS	cells	were	observed	and	 found	to	be	
CD30-	positive	 and	 partially	 CD15-	positive	 or	 -	negative	
(Figure 2).	In	addition,	13/32	(40.6%)	patients	were	CD20-	
positive,	and	10/27	(37.0%)	patients	were	CD79a-	positive.
It	 was	 difficult	 to	 distinguish	 between	 polymorphic	
B-	cell	 LPD	 and	 CHL-	type	 because	 CD30-	positive	 HRS	
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cell	was	frequently	observed	in	polymorphic	B-	cell	LPD.	
However,	polymorphic	B-	cell	LPD	was	frequently	accom-
panied	 by	 CD20-	positive	 medium	 to	 large	 sized	 atypical	
monomorphic	 cells,	 which	 were	 not	 observed	 in	 CHL-	
type.	Based	on	these	findings,	we	diagnosed	CHL-	type	in	
this	study.










Of	 the	 20	 patients	 with	 DLBCL-	type	 MTX-	LPD,	 19	 pa-
tients	 had	 a	 PD-	L1	 positivity	 rate	 score	 of	 1	 (Table  3;	
Figure  4A–	C).	 Most	 tumor	 cells	 were	 PD-	L1-	negative,	
and	a	few	were	weakly	PD-	L1-	positive	on	the	membrane;	
1/20	patients	had	a	score	of	4	(Figure 4D–	F).	In	this	pa-
tient,	 tumor	 cells	 had	 a	 diffuse,	 weakly	 PD-	L1-	positive	
pattern	with	a	scattered	strongly	PD-	L1-	positive	pattern.	
The	prognosis	could	not	be	compared	owing	to	the	biased	





Among	 DLBCL-	type	 MTX-	LPD	 cases,	 14/20	 (70.0%)	
had	a	PD-	L1-	positive	microenvironment.	Morphologically,	
it	 was	 speculated	 that	 histiocytes	 and	 fibroblasts	 could	
show	PD-	L1	positivity	in	the	microenvironment	(Table 3;	
Figure 5A,B).	The	period	up	to	the	start	of	chemotherapy	
and	 overall	 survival	 period	 were	 examined	 between	 the	
microenvironment	 PD-	L1-	positive	 group	 and	 the	 neg-





In	 CHL-	type	 MTX-	LPD	 cases,	 all	 patients	 with	 HRS	
cells	 were	 found	 to	 be	 positive	 for	 PD-	L1.	 No	 case	 with	
a	PD-	L1-	positive	rate	of	<5%	was	 found.	However,	even	
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examined	 in	 this	 study,	 10	 patients	 (41.7%)	 had	 a	 PD-	
L1	 positivity	 rate	 of	 score	 4,	 6	 (25.0%)	 had	 a	 score	 of	 3,	
1	(4.2%)	had	a	score	of	2,	and	7	(29.1%)	had	a	score	of	1	
(Table 3).	Figure 6A	shows	the	clinical	management	and	
prognosis	 after	 MTX	 discontinuation	 of	 patients	 with	

















Microenvironment 14 24 0.014
Abbreviations:	CHL,	classic	Hodgkin	lymphoma;	DLBCL,	diffuse	large	B-	
cell	lymphoma;	PD-	L1,	programmed	cell	death-	ligand	1.
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showed	 that	 there	 were	 significantly	 more	 relapses	 in	
the	PD-	L1 high-	expression	group	than	in	the	PD-	L1 low-	
expression	 group	 after	 MTX	 discontinuation,	 requiring	
additional	chemotherapy	(Figure 6A,	p < 0.05).	However,	
the	overall	survival	was	not	significantly	different	between	
the	 PD-	L1  high-	 and	 low-	expression	 groups	 (Figure  6B,	






We	 compared	 clinical	 findings,	 such	 as	 performance	
status	and	CS	at	the	time	of	diagnosis	of	CHL-	type	MTX-	
LPD,	 between	 the	 groups,	 that	 is,	 the	 PD-	L1  high-	 and	
low-	expression	 groups.	 However,	 although	 there	 were	
no	characteristic	differences	in	clinical	findings	between	




L1	 positivity	 was	 also	 noted	 in	 the	 microenvironment	
(Table  3).	 PD-	L1-	positive	 cells	 in	 the	 microenvironment	
were	 mainly	 macrophages,	 epithelioid	 cells,	 and	 histio-
cytes.	 Furthermore,	 12	 cases	 that	 had	 PD-	L1-	positive	
histiocytes	with	a	rosette	structure	surrounding	the	HRS	
cells	(Figure 7A)	were	compared	with	12	cases	in	which	
histiocytes	 surrounding	 HRS	 cells	 were	 PD-	L1-	negative	





















therapy.	 Of	 the	 DLBCL-	type	 MTX-	LPD	 analyzed	 in	 this	
study,	only	one	case	had	high-	PD-	L1	expression	levels	in	
tumor	 cells.	 The	 patient	 was	 seriously	 ill	 at	 the	 time	 of	
MTX-	LPD	diagnosis,	and	chemotherapy	was	immediately	
administered;	therefore,	the	effect	of	MTX	discontinuation	
could	 not	 be	 determined.	The	 patient	 received	 a	 similar	






















Follow (month)  
P = 0.214 
Follow (month)  
































discontinuation.	 However,	 the	 patient	 was	 also	 negative	
for	 EBER,	 which	 is	 also	 associated	 with	 poor	 progno-
sis11,20,21;	 further	 investigation	 is	warranted	regarding	 its	
pathophysiology.
We	also	analyzed	PD-	L1	expression	 in	 the	 tumor	mi-
croenvironment.	The	expression	 rate	was	 similar	 to	 that	
reported	 by	 Kohno	 et	 al.22	 However,	 no	 association	 was	
found	 between	 PD-	L1	 expression	 in	 the	 microenviron-
ment	and	the	prognosis	of	patients.	According	to	Kiyasu	
et	al.,	PD-	L1	expression	in	tumor	cells	is	correlated	with	
poor	 prognosis	 in	 de	 novo	 DLBCL,	 but	 PD-	L1	 expres-
sion	 in	 the	 microenvironment	 is	 not.23	 Based	 on	 these	
results,	we	suggest	that	PD-	L1	expression	in	the	microen-
vironment	might	not	be	associated	with	the	spontaneous	




treatment	 of	 de	 novo	 CHL	 is	 now	 being	 adopted.15–	17,24	
In	 this	 study,	 we	 investigated	 the	 PD-	L1-	positive	 rate	 of	
HRS	cells	in	CHL-	type	MTX-	LPD	and	found	it	to	be	lower	







clinical	 course	 of	 treatment	 after	 MTX	 discontinuation.	
No	significant	correlation	was	 found	between	PD-	L1	ex-
pression	 intensity	 and	 lesion	 disappearance	 after	 MTX	
discontinuation.	However,	 in	 the	PD-	L1 high-	expression	

































     chemotherapy 









*P < 0. 05 
tPD-L1 high expression 
tPD-L1 low expression 
Changes in condion 
aer MTX disconnuaon 
Changes in condion  
aer  MTX disconnuaon 
Number of paents of 
chemotherapy or relapse 
aer MTX disconnuaon 
Number of paents of 
chemotherapy or relapse 





















tPD-L1 high expression 
P = 0.036 
Follow (month)  


















P = 0.807 
tPD-L1  low expression 
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group,	there	were	significantly	more	cases	of	relapse	after	
discontinuation	of	MTX	and	cases	requiring	chemother-
apy	 as	 compared	 with	 the	 PD-	L1  low-	expression	 group.	
These	 findings	 suggest	 that	 the	 higher	 PD-	L1-	positive	
rate	 in	 HRS	 cells	 most	 likely	 results	 in	 lower	 remission	
and	requires	additional	chemotherapy	after	MTX	discon-
tinuation.	Additionally,	 the	time	required	before	chemo-
therapeutic	 intervention	 in	 the	 PD-	L1  high-	expression	
group	 after	 MTX	 discontinuation	 was	 much	 shorter	






no	 significant	 findings	were	 found.	For	 this	 reason,	 it	 is	





more	 likely	 to	 require	 chemotherapy	 after	 MTX	 discon-





Furthermore,	 Kohno	 et	 al.	 reported	 that	 immunos-






clone	 E1LN3.	 It	 has	 been	 suggested	 that	 there	 are	 sev-
eral	types	of	clones	in	immunohistochemical	staining	for	
PD-	L1,	 which	 may	 affect	 the	 staining	 results.	 Moreover,	
PD-	L1	expression	heterogeneity	in	tumor	tissues	also	af-
fects	the	evaluation	of	PD-	L1	expression.	It	is	known	that	
PD-	L1	 expression	 in	 tumor	 cells	 can	 change	 depending	
on	 the	 surrounding	 environment.	 When	 tumor-	specific	
T-	cells	are	activated,	they	produce	INF-	γ	and	attack	can-
cer	 cells,	 but	 cancer	 cells	 express	 PD-	L1	 in	 response	 to	
IFN-	γ.25	 Furthermore,	 PD-	L1	 expression	 is	 enhanced	 by	







and	PD- L2	 is	 amplified	 in	gastric	 cancer	and	malignant	
lymphoma.26	 In	particular,	 in	de	novo	CHL,	abnormali-




expression (n = 8) p- value
B	symptoms 58.3%	(7/12) 20%	(1/5) 0.294
PS	≥2 18.8%	(3/16) 12.5%	(1/8) 1.000
CS	≥3 75%	(12/16) 75%	(6/8) 1.000
Extranodal	disease 25%	(4/16) 50%	(4/8) 0.363
Extranodal	disease	≥2 2 2
Alb	(<4.0 g/dl) 66.7%	(8/12) 50%	(3/6) 0.627










LDH	above	normal 50.0%	(8/16) 12.5%	(1/8) 0.178
sIL-	2R
Median	(U/ml) 1938 553.5
sIL-	2R	above	normal 86.7%	(13/15) 62.5%	(5/8) 0.208
Abbreviations:	CS,	clinical	stage;	LDH,	lactate	dehydrogenase;	PD-	L1,	programmed	cell	death-	ligand	1;	
PS,	Eastern	Cooperative	Oncology	Group	performance	status;	siL-	2R,	soluble	interleukin-	2	receptor.





14 |   GION et al.
In	this	study,	fluorescence	in	situ	hybridization	of	PD- L1/
PD- L2	 could	 not	 be	 performed,	 but	 it	 is	 highly	 possible	






using	 an	 antibody	 that	 recognizes	 the	 C-	terminal	 (e.g.,	
clone	 SP142	 and	 E1LN3)	 may	 result	 in	 a	 false	 negative.	




PD-	L1	 is	 expressed	 in	 immune	 cells,	 such	 as	 T-	cells,	





not	 included	 in	 this	cohort,	 in	 the	past,	 in	patients	who	
underwent	lymph	node	biopsy	after	MTX	discontinuation	
at	our	institution,	necrosis	in	the	center	of	the	lesion	with	
surrounding	 abundant	 CD8-	positive	 T-	cells	 was	 noted	
(Figure  S1).	 In	Tokuhira	 et	 al.,	 the	 absolute	 lymphocyte	











5 	 | 	 CONCLUSIONS
Compared	 with	 DLBCL-	type	 MTX-	LPD,	 CHL-	type	
MTX-	LPD	was	not	resolved	after	MTX	discontinuation	
alone,	and	required	chemotherapy	in	many	cases.	In	ad-
dition,	 PD-	L1	 expression	 was	 found	 to	 be	 significantly	
higher	 in	 patients	 with	 CHL-	type	 than	 in	 those	 with	
DLBCL-	type	 MTX-	LPD.	 Patients	 with	 CHL-	type	 MTX-	
LPD	 with	 high	 PD-	L1	 expression	 tended	 to	 have	 exac-
erbations	and	relapses	after	MTX	discontinuation.	Our	
study	suggests	that	the	PD-	1/PD-	L1	pathway	is	involved	
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P = 0.796 
Follow (month)  
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